StockData
ALX Oncology Holdings Inc logo

ALX Oncology Holdings Inc (ALXO) stock

ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$0.97−0.03 (-3.47%)

Close on Nov 18, 2026Market cap $134.14MP/E –Yield –

ALX Oncology ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

ALX Oncology's ebitda for the twelve months ending Jun 30, 2026 was -$81.95M. For fiscal 2025 it was -$103.32M. The highest annual figure on record is -$13.25M in fiscal 2018.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$103.32M–
FY2024Dec 31, 2024-$141.60M–
FY2023Dec 31, 2023-$169.44M–
FY2022Dec 31, 2022-$127.09M–
FY2021Dec 31, 2021-$83.50M–
FY2020Dec 31, 2020-$43.46M–
FY2019Dec 31, 2019-$18.75M–
FY2018Dec 31, 2018-$13.25M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$17.93M–
Q1 FY2026Mar 31, 2026-$18.82M–
Q4 FY2025Dec 31, 2025-$22.87M–
Q3 FY2025Sep 30, 2025-$22.33M–
Q2 FY2025Jun 30, 2025-$26.45M–
Q1 FY2025Mar 31, 2025-$31.61M–
Q4 FY2024Dec 31, 2024-$30.40M–
Q3 FY2024Sep 30, 2024-$32.37M–
Q2 FY2024Jun 30, 2024-$41.33M–
Q1 FY2024Mar 31, 2024-$37.55M–
Q4 FY2023Dec 31, 2023-$47.82M–
Q3 FY2023Sep 30, 2023-$53.08M–
Q2 FY2023Jun 30, 2023-$36.58M–
Q1 FY2023Mar 31, 2023-$31.99M–
Q4 FY2022Dec 31, 2022-$32.11M–
Q3 FY2022Sep 30, 2022-$36.58M–
Q2 FY2022Jun 30, 2022-$33.69M–
Q1 FY2022Mar 31, 2022-$24.69M–
Q4 FY2021Dec 31, 2021-$28.44M–
Q3 FY2021Sep 30, 2021-$24.58M–
Q2 FY2021Jun 30, 2021-$16.30M–
Q1 FY2021Mar 31, 2021-$14.20M–
Q4 FY2020Dec 31, 2020-$17.82M–
Q3 FY2020Sep 30, 2020-$9.71M–
Q2 FY2020Jun 30, 2020-$10.69M–
Q1 FY2020Mar 31, 2020-$5.13M–
Q4 FY2019Dec 31, 2019-$7.62M–
Q3 FY2019Sep 30, 2019-$2.93M–
Q2 FY2019Jun 30, 2019-$4.09M–

More ALX Oncology figures

See a number that looks wrong?